BOSTON ORTHOKERATOLOGY (OPRIFOCON A) SHAPING LENSES FOR OVERNIGHT WEAR FOR B&L VISION SHAPING TREATMENT

Lens, Contact, Orthokeratology, Overnight

FDA Premarket Approval P010062 S001

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for the protocol to be used to add contact lens finishing laboratories to manufacture the subject device. The device, as modified, will be marketed under the trade name boston orthokeratology (oprifocon a) shaping lens for overnight wear for bausch & lomb vision shaping treatment and is indicated for use in the reduction of myopic refractive error in non-diseased eyes. The lenses are indicated for overnight wear for the temporary reduction of myopia up to 5. 00 diopters with eyes having astigmatism up to 1. 5 diopters. The lenses may only be disinfected using a chemical disinfection system. Note: to maintain the orthokeratology effect of myopia reduction, overnight lens wear must be continued on a prescribed schedule. Failure to do so can affect daily activities (e. G. , night driving), visual fluctuations and changes in intended correction.

DeviceBOSTON ORTHOKERATOLOGY (OPRIFOCON A) SHAPING LENSES FOR OVERNIGHT WEAR FOR B&L VISION SHAPING TREATMENT
Classification NameLens, Contact, Orthokeratology, Overnight
Generic NameLens, Contact, Orthokeratology, Overnight
ApplicantBAUSCH & LOMB
Date Received2004-07-06
Decision Date2004-08-02
PMAP010062
SupplementS001
Product CodeNUU
Advisory CommitteeOphthalmic
Supplement TypeReal-time Process
Supplement ReasonLabeling Change - Indications/instructions/shelf Life/tradename
Expedited ReviewNo
Combination Product No
Applicant Address BAUSCH & LOMB 1400 North Goodman St. rochester, NY 14603-0450

Supplemental Filings

Supplement NumberDateSupplement Type
P010062Original Filing
S011 2018-05-25 Real-time Process
S010 2016-06-27 30-day Notice
S009 2011-05-31 30-day Notice
S008 2010-10-20 Normal 180 Day Track No User Fee
S007 2009-10-13 Normal 180 Day Track No User Fee
S006 2008-01-31 Real-time Process
S005 2006-12-21 Real-time Process
S004 2006-01-27 135 Review Track For 30-day Notice
S003 2005-04-18 Normal 180 Day Track No User Fee
S002 2004-09-01 Real-time Process
S001 2004-07-06 Real-time Process

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.